Watch SCI Pharmtech Inc for free: we tell you when fair value or trend changes.

SCI Pharmtech Inc (4119) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of SCI Pharmtech Inc stock TWD 19.77, price TWD 50.80, that is 61.1% below the price, quality 38 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

16 models, one by oneBear 14.82 TWD to bull 24.71 TWD Growth analysisrevenue history, year by year Quality 38/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0004119003

Broad data Nov 4, 2026

SCI Pharmtech Inc

4119 · TW

Very expensive, weak quality

Our calculation puts a fair price 61% below what the stock costs today.

Low debt

Broad data

Thin margins · 4.8% net margin (TTM)

Revenue last quarter 27% below a year ago.

Fair value 19.77 TWD · Strongly overvalued

Quality 38/100

Weak Growth (revenue 5y −13.0 %/yr in TWD)

Negative free cash flow

1.5% dividend yield · Pays more than it earns

Trails peers (2/13)

Narrow moat 26/100 · thin data

Watch SCI Pharmtech Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 40.40 TWD – 115.66 TWD · fair‑value band 14.82 TWD – 24.71 TWD · the 50.80 TWD price screens above the 19.77 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow SCI Pharmtech in your weekly email

Every Wednesday you see whether SCI Pharmtech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals.

Show moreShow less

The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, and valproic acid; and develops benserazide, CBN, and CBDv. It also provides intermediate products, such as diethyl isobutyl malonate, benzhydrylamine, 1-Benzhydrylazetidin-3-ol, azetidin-3-ol hydrogenchloride, 1-(2-hydroxyphenyl)-3-phenylpropan-1-one, ritalinic acid, d-ritalinic acid HCl, pyrogallol aldehyde, menthadienol, 5-pentylbenzene-1,3-diol olivetol, methyl 2,4-dihydroxy-6-pentylbenzoate, ethyl 2,4-dihydroxy-6-pentylbenzoate ethyl olivetolate, divarinol, lisdexamfetamine intermediate, UDP-GIcNAz, and UDP-GaINAz. In addition, the company offers customized production services.

It operates in Italy, Spain, the Netherlands, Belgium, the United States, Japan, Germany, Taiwan, Switzerland, and internationally. SCI Pharmtech, Inc. was incorporated in 1987 and is based in Taoyuan City, Taiwan.

Stock analysis

SCI Pharmtech Inc (4119) currently trades at 50.80 TWD, while our model-based Fair Value estimate is 19.77 TWD, 61% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Asset-Based group reads highest at a median of 30.08 TWD per share, and 1 of the 16 models we run sit above the 50.80 TWD price.

Bear case: the Earnings-Based group reads lowest at 7.02 TWD, and 15 of the 16 models stay below the price. Data coverage for this calculation is high.

Scenario range: 14.82 TWD (bear) to 24.71 TWD (bull), the price of 50.80 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

SCI Pharmtech Inc reported revenue of 1.3B TWD in FY2025 versus 864M TWD in FY2021, a compound +11.7%/yr. Reported net income was 107M TWD in FY2025, compounding +17.8%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Key figures

Market cap 6.1B TWD (≈ $185M) Micro · P/E ratio 99.6 · P/S ratio 4.82 · EPS (TTM) 0.5100 TWD · Dividend yield 1.5% · Net margin 4.8% · Return on equity 1.1% · Return on assets (EBIT) 3.4% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).

What moves the price

The share trades about 15% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −61%, 4119 screens richer than that median.

Fair Value models

Bear 14.82 TWD Fair Value 19.77 TWD Bull 24.71 TWD

Price 50.80 TWD · Downside -61.1%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

EPV 6.26 TWD 7.15 TWD 7.87 TWD 74

Residual Income 25.11 TWD 26.28 TWD 28.21 TWD 74

ROIC Compounder 6.26 TWD 7.15 TWD 7.87 TWD 70

All 16 models by family

Earnings-Based

Graham-Dodd 6.11 TWD 20.93 TWD 28.08 TWD 62

Lynch FV 4.82 TWD 6.88 TWD 8.95 TWD 59

PEG = 1.0 4.82 TWD 6.88 TWD 8.95 TWD 55

EPV 6.26 TWD 7.15 TWD 7.87 TWD 74

Dividend Discount

Gordon GGM 9.91 TWD 16.10 TWD 20.44 TWD 66

DDM Multi-Stage 9.91 TWD 15.30 TWD 17.37 TWD 65

Multiples

P/E Multiple 14.82 TWD 19.77 TWD 24.71 TWD 63

P/S Multiple 11.46 TWD 15.27 TWD 19.09 TWD 58

P/B Multiple 151.51 TWD 202.01 TWD 252.51 TWD 55

EV/EBIT 8.81 TWD 14.33 TWD 19.85 TWD 64

EV/EBITDA 28.11 TWD 40.07 TWD 52.02 TWD 67

EV/Revenue 4.07 TWD 9.13 TWD 14.20 TWD 51

Asset-Based

NCAV (Graham) 22.45 TWD 30.08 TWD 44.89 TWD 54

Economic Profit

Residual Income 25.11 TWD 26.28 TWD 28.21 TWD 74

ROIC Compounder 6.26 TWD 7.15 TWD 7.87 TWD 70

Growth Earnings

Growth-Adj P/E 12.61 TWD 18.02 TWD 23.43 TWD 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20

How much profit the company makes from its sales and capital

Quality Growth 12

Are margins and returns getting better?

Cashflow 40

Do the profits arrive as real cash?

Financial strength 79

Debt, balance sheet and risk of trouble

Investment 24

Does it invest with discipline instead of growing at any price?

Low Volatility 85

How calm the share price moves, does not count

Price momentum 42

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 35

Distance to the 52-week high, does not count

New shares 68

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

−11.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.3%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−13.0%

Start year 2020 (pandemic). Over 10 years: −2.9% a year

Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.3%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

−19.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year−21.2%

Dividend (yield on the price)1.5%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−22.8% vs −12.6%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 12%

Pace: the 5-year rate starts in 2020 (pandemic)

⚠ Revenue per share shrinking 2.1%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

4119 screens overvalued: fair value 61% below the price. Compare with Merck KGaA →

Compare SCI Pharmtech Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 2/13 measures

Overall it trails its industry peers.

Valuation

Quality Score 38 · Bottom 25%

Fair Value upside −61.1% · Bottom 25%

Profitability

Return on equity (12 months) 1.1% · Below median

Return on assets 1.6% · Below median

Net margin (12 months) 4.8% · Below median

Operating margin (12 months) 3.4% · Below median

Growth and dividend

Revenue growth (quarter YoY) −26.6% · Bottom 25%

Dividend yield (12 months) 1.5% · Below median

Balance sheet

Debt / equity 0.05× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 99.6× · Priciest 25%

P/B 1.13× · Cheaper than median

P/S (12 months) 4.82× · Priciest 25%

EV/EBITDA 17.7× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 15

FUTURE (revenue growth)0 · sector 25

PAST (return on equity)4 · sector 29

HEALTH (low debt)98 · sector 96

DIVIDEND (yield)30 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Zoetis Inc ZTS	$79.40	$113.53	+43%	vs 4119
Jiangsu Hengrui Pharmaceuticals Co 600276	¥50.43	¥55.21	+9%	vs 4119
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,860	₹1,947	+5%	vs 4119
Haleon plc HLN	$9.14	$8.61	−6%	vs 4119
Merck KGaA MRK	€148.75	€109.18	−27%	vs 4119
Galderma Group GALD	CHF 191.75	CHF 109.86	−43%	vs 4119
Takeda Pharmaceutical Company TAK	$21.02	$11.31	−46%	vs 4119
Teva Pharmaceutical Industries Limited TEVA	$42.61	$20.74	−51%	vs 4119
Sandoz Group SDZ	CHF 83.78	CHF 39.70	−53%	vs 4119
Divi's Laboratories Limited DIVISLAB	₹10,321	₹1,567	−85%	vs 4119

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SCI Pharmtech Inc: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/4119?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/4119.TW.svg" width="360" height="84" alt="SCI Pharmtech Inc: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "SCI Pharmtech Inc Fair Value". https://www.fairvalue-calculator.com/stock/4119

Frequently asked questions

Is SCI Pharmtech Inc (4119) overvalued or undervalued?

As of Nov 4, 2026, our model estimates a fair value of 19.77 TWD versus a price of 50.80 TWD, about 61% lower (overvalued).

What is the fair value of 4119?

Our model-based fair value for SCI Pharmtech Inc is 19.77 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 50.80 TWD.

What is the quality score of 4119?

SCI Pharmtech Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for SCI Pharmtech Inc (4119)?

Our model-based price target is the fair value of 19.77 TWD (as of Nov 4, 2026) from 16 valuation models. Cautious scenario 14.82 TWD, optimistic scenario 24.71 TWD. It is a calculation from audited fundamentals, not an analyst target.

What is the SCI Pharmtech Inc stock forecast for 2026?

Our models put fair value at 19.77 TWD, about 61% lower versus a price of 50.80 TWD (overvalued). Cautious scenario 14.82 TWD, optimistic scenario 24.71 TWD. The calculation is refreshed regularly with new filings.

What is the revenue of SCI Pharmtech Inc (4119)?

SCI Pharmtech Inc reported trailing-twelve-month revenue of about 1.3B TWD (latest available figure, as of Nov 4, 2026).

Does SCI Pharmtech Inc pay a dividend?

SCI Pharmtech Inc currently shows a dividend yield of 1.48% relative to its recent price (as of Nov 4, 2026).

How much is the dividend of SCI Pharmtech Inc (4119) and when is the ex-dividend date?

SCI Pharmtech Inc pays a dividend of 0.75 TWD per share a year, a dividend yield of 1.5%. The last ex-dividend date was Jul 1, 2026. The payout ratio is 147% of earnings. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.

What is the intrinsic value of SCI Pharmtech Inc (4119)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SCI Pharmtech Inc it is 19.77 TWD per share (as of Nov 4, 2026), against a price of 50.80 TWD. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).

Is SCI Pharmtech Inc stock overvalued or undervalued in 2026?

As of Nov 4, 2026, 4119 trades above its calculated fair value: price 50.80 TWD, fair value 19.77 TWD, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 4119?

No. The price is what the market pays today (50.80 TWD); the fair value is what the company's own numbers justify (19.77 TWD). For SCI Pharmtech Inc the two are 31.03 TWD per share apart. That gap is exactly why we show both numbers side by side.

How much is SCI Pharmtech Inc worth?

The market values SCI Pharmtech Inc at about 6.1B TWD (market capitalisation, as of Nov 4, 2026). Per share that is 50.80 TWD; our models calculate a fair value of 19.77 TWD per share.

What do the bullish and bearish scenarios say about 4119?

Our models span a range for SCI Pharmtech Inc: cautious scenario 14.82 TWD, base 19.77 TWD, optimistic 24.71 TWD per share (as of Nov 4, 2026, price 50.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 4119?

SCI Pharmtech Inc trades at a price-to-earnings ratio of 99.6 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 19.77 TWD is built from several models across several years. Other multiples: P/B 1.1, P/S 4.8, EV/EBITDA 17.7.

How solid is the balance sheet of SCI Pharmtech Inc (4119)?

Balance-sheet figures for SCI Pharmtech Inc (as of Nov 4, 2026): return on equity 1.1%, debt of 0.05 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.

How far is 4119 from its 52-week high?

SCI Pharmtech Inc trades at 50.80 TWD, about 15% below its 52-week high of 59.70 TWD and 26% above the low of 40.40 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 19.77 TWD is for.

Which stocks are comparable to SCI Pharmtech Inc?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is SCI Pharmtech Inc stock attractive at the current price?

The data as of Nov 4, 2026: price 50.80 TWD, calculated fair value 19.77 TWD (−61%), Quality Score 38/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 4119 calculated?

We run SCI Pharmtech Inc through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 19.77 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.3% above its aggregate fair value. SCI Pharmtech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of SCI Pharmtech Inc (4119)?

The closing price on Nov 9, 2026 was 50.80 TWD. Our model-based fair value is 19.77 TWD, about 61% lower (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with SCI Pharmtech Inc right now?

The price sits above even our optimistic bull case (24.71 TWD). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.

Where does the earnings growth of SCI Pharmtech Inc (4119) come from?

Earnings per share at SCI Pharmtech Inc grew −2.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share −3.5 %, EBIT margin −6.9 %, tax rate +0.3 %, residual (interest, one-offs) +8.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of SCI Pharmtech Inc

How large is the market capitalisation of SCI Pharmtech Inc (4119)?

The market capitalisation of SCI Pharmtech Inc is 6.1B TWD (≈ $185M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of SCI Pharmtech Inc (4119)?

The price-to-sales ratio of SCI Pharmtech Inc is 4.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of SCI Pharmtech Inc (4119)?

Earnings per share at SCI Pharmtech Inc are 0.5100 TWD (price ÷ EPS = P/E 99.6). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of SCI Pharmtech Inc (4119)?

The dividend yield of SCI Pharmtech Inc is 1.5% (payout 147%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of SCI Pharmtech Inc (4119)?

The net margin of SCI Pharmtech Inc is 4.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of SCI Pharmtech Inc (4119)?

The return on equity (ROE) of SCI Pharmtech Inc is 1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of SCI Pharmtech Inc (4119)?

On an EBIT basis the return on assets of SCI Pharmtech Inc is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of SCI Pharmtech Inc (4119)?

The operating margin of SCI Pharmtech Inc is 3.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at SCI Pharmtech Inc (4119)?

Revenue at SCI Pharmtech Inc is growing −26.6% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at SCI Pharmtech Inc (4119)?

Earnings per share at SCI Pharmtech Inc are growing −35.3% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does SCI Pharmtech Inc (4119) generate?

The free cash flow of SCI Pharmtech Inc is −390M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does SCI Pharmtech Inc (4119) carry?

The net debt of SCI Pharmtech Inc is 927M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch SCI Pharmtech Inc in the live analysis

One click puts SCI Pharmtech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.